E-M-TOPi

E-M-TOPi (also known as E-M ADC) is a preclinical-stage bispecific antibody-drug conjugate (ADC) developed by Shanghai Hengrui Pharmaceutical. It targets both epidermal growth factor receptor (EGFR) and mucin 1 (MUC1), which are highly co-expressed in various solid tumors, including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), and breast cancer. E-M-TOPi consists of an EGFR-MUC1 bispecific antibody conjugated to a topoisomerase I inhibitor (TOPi) payload via a cleavable linker. To minimize on-target, off-tumor toxicity in normal tissues where EGFR is widely expressed, the binding affinity of the antibody's EGFR arm is engineered to be weaker than its MUC1 arm, thereby enhancing selectivity for dual-expressing tumor cells. In preclinical studies, E-M-TOPi demonstrated potent, dose-dependent tumor growth inhibition and regression in xenograft models.

Other names

E-M ADCEM-TOPi